MedTrace Logo

Universal HIV Screening and Targeted HCV Screening in Emergency Department

NCT03595527 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6350

Last updated 2023-02-10

Study results available
· View outcomes & findings →

Summary

Cross-sectional study of patients consulting in the emergency room of the Centre hospitalier de l'Université de Montréal (CHUM), to assess the implementation of an "opt-out" screening program for HIV and HCV and prospective follow-up for 3 months of positive cases.

Conditions

  • Hepatitis C
  • Hiv

Interventions

DIAGNOSTIC_TEST

HIV and HCV screening

HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott

Sponsors & Collaborators

  • Ministere de la Sante et des Services Sociaux

    collaborator OTHER

  • Gilead Sciences

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Centre hospitalier de l'Université de Montréal (CHUM)

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
73 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-10
Primary Completion
2019-10-10
Completion
2020-10-10

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03595527 on ClinicalTrials.gov